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APOE   4 allele is associated with impaired memory function-
ing in both middle-aged and old subjects with MCI, although 
the memory function affected varies with age. Its effect on 
memory function may be dependent on underlying AD pa-
thology in elderly subjects, but not in middle-aged sub-
jects. 
 
Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 The apolipoprotein E (APOE)   4 allele is a major risk 
factor for Alzheimer’s disease (AD)  [1] and is associated 
with memory impairment both in subjects with AD and 
non-demented subjects  [2–4] . The APOE   4 allele may 
also affect memory function in subjects with mild cogni-
tive impairment (MCI)  [5–7] . MCI refers to cognitive im-
pairment in subjects without dementia, and is associated 
with an increased risk for AD  [8] . The relation between 
the APOE   4 allele and memory function in MCI is still 
poorly understood. It is not clear whether the effect of 
APOE on memory function is mediated by underlying 
AD pathology  [9] , or is an independent effect of the APOE 
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 Abstract 
 Background: Memory problems are a main feature of mild 
cognitive impairment (MCI) and may be related to the apoli-
poprotein E (APOE)   4 allele. We investigated whether the 
effect of the APOE genotype on memory in subjects with 
MCI was dependent on age and underlying Alzheimer dis-
ease (AD) pathology.  Methods: Subjects with MCI (n = 180) 
were selected from a memory clinic setting. Subjects with at 
least one APOE   4 allele (n = 83) were compared to non-car-
riers on several memory measures. Subjects were reassessed 
5–10 years later in order to identify those who developed AD. 
 Results: In the middle-aged subgroup, the APOE   4 allele 
was most strongly related to decreased subjective organiza-
tion and in the old subgroup to a decreased delayed recall. 
After excluding subjects with incipient AD (n = 33), results 
remained similar in the middle-aged subgroup, but in the 
old subgroup the APOE genotype was no longer associated 
with memory dysfunction.  Conclusion: The presence of the 
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genotype  [10] . In addition, in order to better understand 
the relation between APOE genotype and memory func-
tion it would be important to know whether the effect of 
APOE genotype is dependent on age, because underlying 
pathology in MCI may vary with age  [2, 11] . In addition, 
it would be important to know which aspect of memory 
is most severely affected, because this may give an indica-
tion of which brain regions are involved. Previous studies 
in subjects with MCI, however, were conducted in elderly 
subjects only  [6, 7] , and mainly investigated learning and 
delayed recall.
 The aims of the present study were to investigate the 
effect of the APOE   4 allele on memory function in mid-
dle-aged (40–59 years) and elderly (60–85 years) subjects 
with MCI from a memory clinic setting and to investigate 
whether the effect of APOE   4 allele on memory function 
was dependent on underlying AD pathology. To that end 
we followed subjects for 5–10 years and repeated analyses 
after exclusion of subjects who developed AD during this 
period. Besides learning and delayed recall, we also inves-
tigated memory measures that have not been investigated 
before such as primacy, recency, retention, intrusions, 
subjective organization, and serial clustering. Subjective 
organization and serial clustering are learning strategies 
that are used by a subject to learn new information. These 
strategies are impaired in early AD  [12–14] .
 Methods 
 Subjects 
 Subjects were selected from an ongoing longitudinal study of 
non-demented subjects referred to the Maastricht Memory Clin-
ic. The Memory Clinic is an outpatient clinic of the University 
Hospital Maastricht  [15] . The design of the study has been de-
scribed in detail elsewhere  [8, 15] . Consecutive patients were in-
cluded at the time of the first visit to the Memory Clinic. Inclusion 
criteria were age 40 years or older, and MCI, defined as a score of 
2 or 3 on the Global Deterioration Scale (GDS)  [16] . This broad 
definition of MCI is consistent with that of other studies  [17–19] . 
It was used because subjects with AD in the predementia stage do 
often not meet more strict criteria of MCI, such as criteria for am-
nestic MCI  [20–22] . Exclusion criteria were dementia at baseline 
and an apparent cause for their cognitive impairment, such as 
cerebrovascular disorders, brain trauma, endocrine disorders or 
psychiatric disorders other than mild affective disorders at base-
line  [23] . Subjects included in this study were referred to the Mem-
ory Clinic by general practitioners (76%), neurologists (6%), psy-
chiatrists (12%) or others (6%).
 For the present study we selected those subjects eligible for the 
5- or 10-year follow-up (n = 453). During this period five versions 
of the Auditory Verbal Learning Test (AVLT)  [24] were used at 
baseline. In order to avoid a version effect of the AVLT, we only 
included subjects with the version that was most commonly used 
(n = 367). Subjects with this version had similar age, sex, level of 
education, Mini Mental State Examination (MMSE) score  [25] , 
GDS score  [16] and Blessed Dementia Rating Scale score (BDS) 
 [26] as subjects with other versions of the AVLT. Next we exclud-
ed subjects on whom APOE genotyping had not been performed 
(n = 187). The final study sample consisted of 180 subjects. Data 
on APOE genotype was mainly unavailable because blood for ge-
notyping was collected at follow-up during a specific time period. 
In addition, a few subjects refused APOE genotyping. Subjects 
whose APOE status was not available were significantly older 
(60.7 vs. 57.0 years, p = 0.001) compared to subjects whose APOE 
status was known. Both groups were comparable with respect
to educational level, sex distribution, MMSE score, Hamilton
Depression Rating Scale (HDRS) score  [27] and total delayed re-
call at baseline, as well as percentage of subjects with AD at fol-
low-up.
 Clinical Assessment at Baseline and Follow-Up 
 At baseline, all subjects underwent a standardized assessment, 
which included a detailed history of the subject, a psychiatric, 
neurological, and physical examination, the MMSE  [25] , GDS 
 [16] , BDS  [26] , HDRS  [27] and the appropriate laboratory tests, a 
neuropsychological assessment, and a CT or MRI as described 
elsewhere  [15] . For descriptive purposes we subdivided subjects at 
baseline into five MCI groups based on the neuropsychological 
test performances in the domains of memory, attention, executive 
functioning, language, and visuoconstruction, as described else-
where  [8] . Performance in a cognitive domain was considered im-
paired if the score on at least one test from that domain was below 
–1.5 standard deviation (SD) of age-, sex- and education-correct-
ed means of healthy control subjects  [28–30] except for the mea-
sure of visuoconstruction in which impairment was based on a 
qualitative rating  [8] . Subjects without impairment in any domain 
were classified as subjective complaints (n = 53); subjects with 
only impairments in one non-memory domain as non-amnestic 
MCI single domain (n = 33), subjects with only impairments in 
more than one non-memory domain as non-amnestic MCI mul-
tiple domain (n = 33), subjects with impairment in only the mem-
ory domain as amnestic MCI single domain (n = 13), and subjects 
with both impairments in memory and non-memory domains as 
amnestic MCI multiple domain (n = 47). One subject could not be 
classified, because non-memory tests had not be done. The crite-
ria for non-amnestic MCI and amnestic MCI also require intact 
activities of daily living  [31] . This was operationalized as the ab-
sence of dementia and a score below 4 on the GDS, which was part 
of the inclusion criteria of the study, in agreement with previous 
studies  [20] .
 Two, 5 and 10 years after baseline, the subjects were invited for 
a follow-up assessment. This assessment included a standardized 
questionnaire about medical history and cognitive complaints, 
the MMSE, GDS, BDS, HDRS, and an extensive neuropsycho-
logical assessment comparable to the baseline assessment. Sub-
jects who refused to come for the follow-up were assessed via a 
telephone interview, which included a standardized question-
naire about medical history and cognitive complaints, and the 
Telephone Interview for Cognitive Status  [32] . The diagnosis of 
dementia and AD was made independently by both a neuropsy-
chiatrist and a neuropsychologist according to the DSM-IV and 
NINCDS-ADRDA criteria  [33, 34] . Both were blinded to the base-
line results. If disagreement on the diagnosis occurred, a consen-
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sus meeting was held. Subjects who were diagnosed as being de-
mented at follow-up were not invited for the next follow-up.
 Outcome at Follow-Up 
 The average follow-up duration was 8.7 years. Because blood 
for genotyping was collected at follow-up, all subjects had at least 
one follow-up. Of the 180 subjects included at baseline, 140 sub-
jects had been in the study long enough to be contacted for the 
10-year follow-up and cognitive outcome was available for 120 
(86%) of them, the other subjects (n = 40) only had a 5-year fol-
low-up. Reason for no outcome at the 10-year follow-up was be-
cause the subjects refused (n = 6), had died (n = 7), or were un-
traceable (n = 7). Subjects with and without cognitive outcome 
had comparable age, sex distribution, level of education and 
MMSE score. During the total follow-up period 33 subjects (18%) 
had developed AD. After 5 years 25 subjects had developed AD, 
and after 10 years 8. Of those with AD at follow-up, 6 were youn-
ger than 60 years (of whom 5 subjects were carriers of the APOE 
  4 allele) and 27 were older than 60 years (of whom 21 subjects 
were carriers of the APOE   4 allele). Fourteen subjects who de-
veloped AD had a baseline GDS score of 2, and 19 subjects had a 
baseline GDS score of 3.
 Measures of Memory Impairment 
 In the Dutch version of the AVLT  [24, 28] , 15 unrelated mono-
syllabic words are presented 5 times in the same order and after 
each presentation the subject is asked to recall as many words as 
possible. After 20 min, in which non-verbal tests were performed, 
delayed recall was tested. The AVLT can be used to investigate the 
following aspects of verbal memory functioning:
 Learning. Total of correctly remembered words from the 5 im-
mediate recall trials.
 Delayed Recall. Total number of correctly remembered words 
after 20 min.
 Retention. Total delayed recall score divided by the highest 
score at the 5 immediate recall trials, multiplied by 100.
 Intrusion. Number of recalled words in the 5 immediate recall 
trials that were not part of the AVLT.
 Subjective Organization. Subjective organization refers to the 
constancies in response ordering that develop in a series of free 
recalls  [35, 36] . Based on the output order in which the words from 
two successive trials are listed by the subjects, combinations (clus-
ters) of words that are recalled together in these two successive 
trials are identified. These combinations are based on the organi-
zation schema developed by the individual subject, and are not 
dependent on prespecified categorization based on semantic re-
lationships, which is used in several word learning tests such as 
the California Verbal Learning Test  [37] . A bidirectional inter-
trial repetition (ITR) measure was used  [38, 39] . Each time a com-
bination of words is recalled consecutively in one trial and also in 
the next trial (= ITR) the subject gets one point. The bidirection-
al ITR corrects for clusters that occur by chance with the follow-
ing formula: Subjective organization = observed (ITR) – expected 
(ITR), where expected ITR = 2 c ( c – 1)/ h  ! k  [38, 39] . Observed 
ITR is the number of pairs of items recalled on trial  t  and  t +  1 in 
adjacent output positions in either of the two possible orders. For 
example, if after the first trial ‘f lower’ and ‘car’ were mentioned 
after each other and in the second trial ‘f lower’ was followed by 
‘car’ or ‘car’ was followed by ‘flower’, this counted as one observed 
ITR. Expected ITR is the expected number of pairs of items,  c is 
the number of common items recalled on both trials  t  and  t +  1, 
 h is the number of items recalled on trial  t , and  k is the number of 
items recalled on trial  t +  1. An outcome of 0 indicates that the 
number of observed ITRs is equal to the number of expected 
ITRs. A score higher than 0 indicates more use of subjective or-
ganization than expected by chance.
 Serial Clustering. Serial clustering is a measure for the repro-
duction of words in the same order as that they were presented. 
This form of clustering indicates a more passive approach to re-
call. Serial clustering was calculated by dividing the number of 
observed serial clusters by the number of serial clusters that could 
be expected to occur by chance  [39, 40] .
 Primacy Effect. Ratio of the number of words remembered 
from the first 3 words of the list divided by 3.
 Recency Effect. Ratio of the number of words remembered 
from the last 3 words of the list divided by 3.
 APOE Genotyping 
 APOE genotype was determined on genomic DNA extracted 
form EDTA-anticoagulated blood using the polymerase chain re-
action technique  [41–43] . Genotyping was done blinded for all 
clinical data. Eighty-three subjects (46%) had one or two   4 alleles 
(APOE+), i.e.   4  4 (n = 8, 4%),   3  4 (n = 69, 38%), and   2  4 (n = 
6, 3%). Ninety-seven subjects (54%) had no   4 allele (APOE–), i.e. 
  3  3 (n = 76, 42%),   2  3 (n = 20, 11%), and   2  2 (n = 1, 0.6%).
 Statistics 
 Statistical analyses were performed using the Statistical Pack-
age for Social Sciences for the Macintosh, version 11. To analyse 
baseline differences between carriers and non-carriers of the 
APOE   4 allele independent t tests were used for continued vari-
ables, and   2 tests for categorical variables. Level of education was 
classified into low (at most primary education), middle (junior 
vocational education), or high (senior vocational education or ac-
ademic training)  [44] . Univariate variance analyses (ANOVA) ad-
justed for age, education and sex were used to test group differ-
ences in memory performance between carriers and non-carriers 
of the APOE   4 allele. To adjust the ANOVA analyses for multiple 
comparisons we used an   -level of 0.01. Stepwise binary logistic 
regression analysis with correction for age, sex and education was 
used to identify the memory variable to which the APOE   4 allele 
was strongest related. All analyses were repeated without subjects 
who had developed AD within the study period of 10 years and 
were performed in the total group and in subjects aged 40–59 
years (middle-aged subgroup) and 60–85 years (older subgroup).
 Results 
 Baseline Characteristics 
 Baseline characteristics of carriers and non-carriers 
of the APOE   4 allele are presented in  table 1 . In the to-
tal group, APOE   4 carriers were about 4 years older, 
had a significantly lower MMSE and delayed recall 
score, a slightly higher GDS score, a lower HDRS score, 
and more often amnestic MCI (45 vs. 24%, p = 0.003) 
compared to non-carriers. Educational level and sex 
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distribution were comparable. In the middle-aged sub-
group, baseline characteristics and distribution of MCI 
subtypes was comparable between subjects with and 
without the APOE   4 allele. In the elderly subgroup, 
APOE   4 carriers had a lower score on the delayed recall 
test than subjects without the APOE   4 allele. The APOE 
  4 allele was more common in subjects older than 60 
years (58%) than in the middle-aged subgroup (40%,
p = 0.015).
 Effect of APOE on Memory Function 
 Memory performances of carriers and non-carriers of 
the APOE   4 allele are presented in  table 2 . In the total 
sample, carriers of the   4 allele had lower scores on learn-
Table 1. Baseline characteristics according to APOE status
All subjects Subjects 40–60 years Subjects 60–85 years
APOE 4–
(n = 97)
APOE 4+
(n = 83)
p APOE 4–
(n = 70)
APOE 4+
(n = 46)
p APOE 4–
(n = 27)
APOE 4+
(n = 37)
p
Age1, years 55.289.2 58.989.9 0.01 50.484.8 51.585.6 0.27 67.685.5 68.185.3 0.73
Education, % low 12 24 0.12 9 20 0.23 22 30 0.76
Sex, % male 57 54 0.74 60 59 0.89 48 49 0.97
MMSE1 28.781.4 28.082.0 0.01 28.981.3 28.781.4 0.51 28.081.6 27.182.3 0.07
Delayed recall (Z score)1 –0.581.3 –1.281.2 <0.001 –0.581.2 –0.881.2 0.10 –0.781.5 –1.781.2 0.006
MCI subgroups
aMCI-SD, % 5 10 0.26 3 9 0.171 11 11 0.97
aMCI-MD, % 19 35 0.014 19 30 0.151 19 42 0.06
naMCI-SD, % 22 14 0.20 22 9 0.07 22 8 0.15
naMCI-MD, % 23 13 0.10 22 20 0.78 26 19 0.50
Subjective complaints, % 31 27 0.61 35 33 0.809 22 21 0.910
GDS1 2.380.5 2.580.5 0.03 2.380.4 2.480.5 0.14 2.480.5 2.780.6 0.17
BDS1 1.381.2 1.581.6 0.26 1.281.3 1.481.6 0.62 1.581.1 1.981.7 0.3
HDRS1 10.785.5 8.886.1 0.032  10.985.7 8.986.4 0.10 10.485.2 8.685.8 0.2
1 Mean 8 SD.
aMCI-SD = Amnestic MCI single domain; aMCI-MD = amnestic MCI multiple domain; naMCI-SD = non-amnestic MCI single 
domain; naMCI-MD = non-amnestic MCI multiple domain; APOE 4– = non-carriers of the APOE 4 allele; APOE 4+ = homozy-
gote or heterozygote carriers of the APOE 4 allele.
Table 2. Effect of the APOE 4 allele on memory function
 All subjects Subjects 40–60 years Subjects 60–85 years
APOE 4–
(n = 97)
APOE 4+
(n = 83)
p value APOE 4–
(n = 70)
APOE 4+
(n = 46)
p value APOE 4–
(n = 27)
APOE 4+
(n = 37)
p value
Learning 41.9810.9 35.4810.3 0.002 43.789.8 38.9810.1 0.035 37.6812.4 30.988.9 0.02
Delayed recall 8.583.4 6.483.5 0.003 9.183.0 8.083.0 0.09 7.084.0 4.483.2 0.01
Subjective organization 1.481.1 0.980.8 0.003 1.681.1 1.080.8 0.009 1.280.9 0.880.8 0.15
Serial clustering 3.181.5 2.781.6 0.16 3.381.5 2.881.4 0.09 2.881.5 2.681.7 0.80
Primacy 0.780.2 0.680.2 0.046 0.880.2 0.780.2 0.08 0.780.2 0.680.2 0.28
Recency 0.680.2 0.680.2 0.10 0.780.2 0.680.2 0.14 0.680.2 0.580.2 0.48
Intrusions 1.982.4 2.483.1 0.40 2.182.6 2.283.0 0.88 1.581.9 2.683.2 0.21
Retention, % 75.5822.3 65.0826.3 0.054  79.6817.5 76.9817.8 0.37 65.0829.4 50.6827.9 0.07
Data are mean 8 SD; p values are uncorrected for multiple testing.
APOE 4– = Non-carriers of the APOE 4 allele; APOE 4+ = homozygote or heterozygote carriers of the APOE 4 allele.
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ing, delayed recall, and subjective organization. None of 
the memory measures showed a significant interaction 
between age and the APOE genotype. In subjects youn-
ger than 60 years, APOE   4 carriers had lower scores on 
learning and subjective organization, while in the elderly 
subgroup APOE   4 carriers had lower scores on learning 
and delayed recall ( table 2 ). After correction for multiple 
comparisons learning did not reach statistical signifi-
cance in the middle-aged and old subgroup.
 Binary logistic regression analyses, adjusted for age, 
sex and education showed that in the total sample the 
APOE   4 allele was most strongly related to learning per-
formance (p = 0.004). In middle-aged subjects, the APOE 
  4 allele was most strongly related to subjective organiza-
tion (p = 0.011), while in the elderly subjects the APOE   4 
allele was most strongly related to delayed recall perfor-
mance (p = 0.02).
 Effect of Underlying AD Pathology 
 When the subjects with AD at follow-up were exclud-
ed from the analyses (6 in the 60– group, and 27 subjects 
in the 60+ group), the APOE   4 allele was associated with 
lower scores on learning in the total group (p = 0.025). In 
middle-aged subjects, the APOE   4 allele was still associ-
ated with lower scores on subjective organization (p = 
0.028), but no longer with learning. In the 60+ group, the 
APOE genotype was no longer associated with any of the 
memory measures.
 Discussion 
 In the present study, we found an effect of the APOE 
  4 allele on various aspects of memory in subjects with 
MCI, which depends on age and underlying AD pathol-
ogy. In elderly subjects, the APOE   4 allele was most 
strongly related to delayed recall performance, compared 
to subjective organization in the middle-aged subgroup. 
The effect of APOE on memory function may have been 
related to underlying AD pathology in subjects over 60 
years, but not in middle-aged subjects.
 The effect of the APOE   4 genotype on delayed recall 
and learning in elderly subjects with MCI is in line with 
previous studies  [5, 6] . It suggests involvement of the me-
dial temporal lobe as this region plays an important role 
in these memory functions. Indeed, there is evidence that 
elderly subjects with MCI with an APOE   4 allele have 
more atrophy in this region compared to subjects without 
an APOE   4 allele  [45] . The effect of the APOE   4 allele 
on memory functioning may have been modulated by the 
degree of underlying AD pathology, since after exclusion 
of subjects who developed AD, the APOE genotype was 
no longer associated with memory performance. This 
finding is consistent with a population-based study in el-
derly subjects which showed that the APOE is no longer 
associated with cognition after correction for amyloid 
load in the brain  [9] . However, the lack of an effect of 
APOE genotype on memory after exclusion of incipient 
AD cases might also have resulted from a lack of statisti-
cal power, because after the exclusion of AD subjects only 
10 subjects older than 60 years carried the APOE   4 al-
lele. It should be noted that we assumed that AD pathol-
ogy was present in subjects who progressed to clinical AD 
at follow-up, but we did not have imaging or cerebrospi-
nal fluid markers to quantify AD pathology more direct-
ly. This may be particularly useful for the younger sub-
jects as it may take longer for these subjects to develop 
clinical AD.
 In subjects younger than 60 years, the   4 allele was 
most strongly associated with subjective organization, 
and to a lesser extent with learning. Subjective organiza-
tion is an effortful learning strategy requiring an active 
reorganization of incoming information to enhance the 
quality of encoding, and is thought to be mediated by the 
prefrontal lobe  [46–49] . In order to investigate whether 
this effect was mediated by impairment in executive 
function, we post hoc repeated the analyses with correc-
tion for Stroop card III score and Trial Making Test B 
score  [50, 51] . In these analyses, subjective organization 
remains significantly related to APOE genotype, which 
suggests that subjective organization problems in APOE 
  4 carriers cannot be explained by impairments in ex-
ecutive functioning. No other studies have investigated 
the effect of APOE on memory in middle-aged subjects 
with MCI, but in healthy young and middle-aged subjects 
the APOE   4 allele did not have an effect on memory 
function  [52] . The lack of effect in young and middle-
aged healthy APOE   4 carriers could be explained by test 
selection, because only measures of learning or delayed 
recall were tested, which was not severely affected by the 
APOE   4 allele in our study. Alternatively, the effect of 
the APOE   4 allele on cognitive function in younger sub-
jects may become apparent only if impairment is severe 
enough to meet criteria of MCI and leads to referral to a 
memory clinic.
 The effect of the APOE   4 allele on memory function-
ing in the middle-aged subgroup seemed not to be modu-
lated by incipient AD, because after exclusion of subjects 
who converted to AD subjective organization remained 
associated with the   4 allele. This could mean that the 
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APOE   4 allele directly affects memory functioning in-
dependently of AD-related pathology, for example by its 
effect on lipid or glucose metabolism  [10] . Another expla-
nation is that the memory problems were related to the 
degree of AD pathology, but that in these middle-aged 
subjects the follow-up interval was not long enough to 
identify everyone who would progress to clinical AD. In 
that case, subjective organization could be a very early 
marker of AD  [12–14] . This may be investigated using 
PET amyloid imaging or cerebrospinal fluid markers of 
AD pathology, which were not available in the present 
study.
 There is ample evidence that the APOE   4 allele af-
fects brain functioning in parietal, temporal and prefron-
tal regions in young to middle-aged subjects who are cog-
nitively intact  [53–55] . The interpretation of these studies 
is still controversial. Some studies suggest that these brain 
abnormalities reflect early AD as AD pathology is found 
in the same regions and may be present decades before 
the onset of dementia  [53, 56] . Others consider this un-
likely and suggest that these abnormalities are a direct 
effect of the APOE genotype on lipid or glucose metabo-
lism that may facilitate the onset of AD at a later age  [57] . 
The effect of APOE on frontal lobe functioning in young 
to middle-aged subjects may explain the effect of APOE 
on subjective organization in the present study  [53, 58–
61] . Although neuroimaging studies in this age range 
showed also impairments in the medial temporal lobe, 
learning and delayed recall were not severely affected in 
the middle-aged subgroup in our study  [57, 60, 62] . One 
explanation is that these memory functions could still be 
compensated for.
 Serial clustering, primacy, recency, intrusions and re-
tention were not related to APOE genotype. Serial clus-
tering, primacy, and recency do not require active orga-
nization of the incoming information and are more re-
lated to working memory and short-term memory 
processes. In general, these aspects of memory function-
ing are relatively less sensitive to neurodegeneration  [14] . 
The lack of an effect of the number of intrusions might 
be explained by the low prevalence of intrusions in the 
total sample. Retention was lower in APOE   4 carriers, 
but did not reach statistical significance.
 The APOE allele distribution in our sample is compa-
rable with that reported in other studies with MCI  [1, 7] . 
The prevalence of the APOE   4 allele in our middle-aged 
subgroup (40%) and in the elderly subgroup (58%) was 
higher than the prevalence of the APOE   4 allele in sub-
jects from the general population aged 40–60 (32%) and 
60–85 years (24%) from the Maastricht Aging Study  [63] . 
This suggests that carriers of the APOE   4 allele more 
often have memory problems leading to a referral to a 
memory clinic than non-carriers, even at a relatively 
young age.
 We used a broad definition of MCI in accordance to 
previous studies  [17–19] . As a result, we also included 
subjects with cognitive complaints in the absence of im-
pairment on cognitive tests (n = 53), although some of 
them (n = 3) had mild functional impairment defined as 
a score of 3 on the GDS. If we excluded subjects with sub-
jective complaints from the analyses, the effect of the 
APOE genotype on memory function remained similar 
in the total sample. In the age subgroups, however, APOE 
  4 was no longer associated with learning and subjective 
organization in the middle-aged subgroup, and with the 
delayed recall score in the older subgroup. This is prob-
ably because we limited the range of memory impairment 
and reduced statistical power due to smaller sample 
size.
 The strengths of the present study include the large 
sample size, the broad age range, the variety of memory 
measures tested, and the long follow-up period to iden-
tify subjects with incident AD. The study also had some 
limitations. Firstly, after exclusion of those who devel-
oped AD the sample size in the older subgroup was small, 
resulting in only 10 subjects older than 60 years who car-
ried an   4 allele. Secondly, because subjects were selected 
from a memory clinic results may not be generalizable to 
other settings and subjects with MCI according to other 
definitions. Thirdly, the follow-up period may be too 
short to identify all subjects who convert to AD. Another 
point is that blood samples for APOE genotyping were 
collected at follow-up only. However, the baseline char-
acteristics of the subjects with data on APOE genotype 
and those without data on APOE genotype were compa-
rable, except regarding age, which was 3 years lower in 
those with genotyping. This suggests that genotyping at 
follow-up may not have introduced a strong bias. Finally, 
we used an indirect measure of AD pathology rather than 
a direct measure such as PET amyloid imaging or cere-
brospinal fluid markers as discussed above.
 In conclusion, the findings of this study, that investi-
gated several aspects of verbal memory across a broad age 
range in clinical subjects with MCI, showed that APOE 
genotype has an effect on memory that is dependent on 
age. In subjects aged 60 years and older, memory func-
tions associated with the medial temporal lobe were pre-
dominantly affected, while in middle-aged subjects 
memory functioning related to the frontal lobe was most 
strongly affected. Together with the observation that 
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memory functioning was dependent on the degree of AD 
pathology in elderly subjects, but not in middle-aged sub-
jects, this suggests that different mechanisms underlie 
the APOE-related memory dysfunction in different age 
groups. Whether the effect of APOE genotype on subjec-
tive organization in middle-aged subjects is indeed an 
AD-independent process needs to be investigated in fu-
ture imaging studies and longitudinal studies with a lon-
ger follow-up.
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